The newly published report titled “Global Prostate Health Market By (Disease Indication(Prostate Cancer, Prostatitis, Alpha Blockers, Benign Prostate Hyperplasia and Others), Treatment(Cytotoxic Agents, Hormone ADT, AR Directed Therapies, PARP Inhibitors and Others), End-User (Hospitals, Specialty Clinics, Homecare And Others), Distribution Channel (Pharmacies, E-Commerce Stores And Others)) – Trends, Industry Competition Analysis, Covid-19 Analysis, Revenue (US$ Billions) and Forecast Till 2034.” of InsightAce Analytic Pvt. Ltd. features detailed industry analysis and an extensive study on the market, exploring its significant factors.
The global Prostate Health market is estimated to reach over USD 91.9 billion by 2034, exhibiting a CAGR of 9.8% during the forecast period.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1402
A man’s prostate can develop cancer, which is called prostate cancer. The gland that makes seminal fluid is little, and in the US, it is the second leading cause of mortality for men. Some forms of prostate cancer are slow-growing, localized only to the prostate gland, and may not have any adverse symptoms. While some may require treatment, others might spread quickly and cause significant harm due to the FDA’s support for new pipeline pharmaceuticals and developing technologies and the market for prostate health, which is expected to experience enormous growth. The government’s FDA approvals are anticipated to generate superior growth prospects for the prostate cancer health industry over the expected time frame.
List of Prominent Players in the Prostate Health Market:
Pfizer Inc.
Lily
Bayer AG
Abbott
GSK plc.
Merck KgaA
ProArc
Nucleai, Inc.
Sanofi
AbbVie Inc
Market Dynamics:
Drivers-
The rise in obesity, the prevalence of benign prostatic hyperplasia (BPH), the increase in prostate cancer incidence, the rise in hormone therapy drug demand, the surge in prostatitis cases, and the investments, funds, and grants for BPH treatment research are the main factors driving the market’s expansion. As people get older, prostate cancer occurs more frequently, and the most common malignancy is prostate cancer in men. Prostate cancer is expected to cause roughly 248,530 new cases and 34,130 deaths in the US in 2021, according to estimates from the American Cancer Society.
Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/1402
Challenges:
Surgery and prescription drugs can also treat BPH, but both have serious side effects. BPH treatment typically involves alpha-blockers, 5-ARIs (5-alpha reductase inhibitors), and other pharmaceutical classes. Alpha-blockers frequently cause adverse symptoms such as rhinitis, orthostatic hypotension, retrograde ejaculation, and dizziness.
Regional Trends:
The North America Prostate Health market is expected to register a significant market share in revenue and is projected to grow at a high CAGR shortly. The expansion of the market (an essential factor in the North American prostate health market) may be ascribed to the target population’s increase, the high incidence of BPH, prostate cancer, and prostatitis, and the significant presence of medical device makers. This market’s expansion has also been aided by advantageous reimbursement rules, high disposable incomes, a robust healthcare system, financing for research, and new product introductions. Besides, Asia Pacific had a substantial share in the Prostate Health market. This results from an ageing male population and rising rates of benign prostatic hyperplasia and prostate inflammation in these nations. As healthcare prices rise and public awareness increases, emerging countries like China, India, and others provide target patient groups. Due to inexpensive labour and favourable market conditions, start-up enterprises focus more on growing their operations throughout developing Asia Pacific nations like China and India.
Recent Developments:
- In June 2021, to treat metastatic castration-resistant prostate cancer, Novartis reported that the FDA had approved 177Lu-PSMA-617, an investigational device therapy (mCRPC).
- In January 2021, Myovant announced a collaboration with Pfizer to market its medication Orgovyx (relugolix).
For Customization: https://www.insightaceanalytic.com/customisation/1402
Segmentation of Prostate Health Market-
By Disease Indication-
- Prostate Cancer
- Prostatitis
- Alpha Blockers
- Benign Prostate Hyperplasia
- Others
By Treatment-
- Cytotoxic Agents
- Hormone ADT
- AR Directed Therapies
- PARP Inhibitors
- Others
By Distribution Channel
- Pharmacy
- E-commerce Stores
- Others
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get More Information :
https://www.insightaceanalytic.com/report/global-prostate-health-market/1402
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
